Investor acquires 21 percent of Biovitrum

Investor AB has acquired 10.697.307 shares in Biovitrum for SEK 556 m., corresponding to 21.4 percent of the capital and 21.5 percent of the votes of the company. The purchase price corresponds to SEK 52 per share. Sellers are Nordic Capital IV, L.P., Nordic Capital IV Beta, C.V., Nordic Capital IV Gamma, C.V., Fyrfond KB, NC IV Limited and Nextgear Invest Limited.

Biovitrum is a Stockholm based specialty biopharma company listed on the OMX Nordic Exchange in Stockholm.

The investment will belong to Operating Investments. It will be valued at the official share price as a listed investment.

The nomination committee of Biovitrum will in connection to this transaction nominate Hans Glemstedt and Peter Sellei, both vice presidents at Investor AB, to the board.

"Biovitrum has a strong position in an industry we know well and like. The company has successfully changed strategy to become an international integrated specialty biopharma company. Biovitrum has today a strong platform for attractive growth through in-licensed, acquired and, over time, own developed products. We look forward to contributing in making it a leading international life science company" says Lennart Johansson, Head of Operating Investments.

INVESTOR AB

For further information:

Fredrik Lindgren, Head of Corporate Communications, +46 8 614 2031, +46 735 524 2031
Oscar Stege Unger, Head of Investor Relations, +46 8 614 2059, +46 70 624 2059